PACIRA BIOSCIENCES, INC. Equity Method Investment, Other than Temporary Impairment
PACIRA BIOSCIENCES, INC. (PCRX) reported Equity Method Investment, Other than Temporary Impairment of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. equity method investment, other than temporary impairment for the quarter ending 2025-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. equity method investment, other than temporary impairment for the quarter ending 2025-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. equity method investment, other than temporary impairment for the quarter ending 2024-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. equity method investment, other than temporary impairment for the quarter ending 2024-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. equity method investment, other than temporary impairment for fiscal 2025 was $11.00M.
- PACIRA BIOSCIENCES, INC. equity method investment, other than temporary impairment for fiscal 2024 was $0.00.
- PACIRA BIOSCIENCES, INC. equity method investment, other than temporary impairment for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. equity method investment, other than temporary impairment for fiscal 2022 was $10.00M.
| Period end | Equity Method Investment, Other than Temporary Impairment 3 month | Equity Method Investment, Other than Temporary Impairment 6 month | Equity Method Investment, Other than Temporary Impairment 9 month | Equity Method Investment, Other than Temporary Impairment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-04 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $11.00M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $11.00M 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $11.00M 10-Q · filed 2026-08-04 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-05 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-02 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $10.00M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $10.00M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |